51 employees
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
2021
$50M
from 5 investors over 5 rounds
CHARM Therapeutics raised $50M on June 9, 2022
Investors: F-Prime Capital Partners, General Catalyst, Braavos Investment Advisers, OrbiMed Advisors and Khosla Ventures